Effects of the K+→π+ννˉK^+\to\pi^+\nu\bar{\nu} and of other processes on the mixing hierarchies in the four-generation model

We analyze in the four-generation model the first measurement of the branching ratio of rare kaon decay $K^+\to\pi^+\nu\bar{nu}$, along with the other processes of $K_L-K_S$ mass difference $\Delta m_K$, CP-violating parameter $\epsilon_K, B_d-\bar{B_d}$ mixing, $B_s-\bar{B_s}$ mixing, $B(K_L\to\mu\bar{\mu})$, and the upper bound values of $D^0-\bar{D^0}$ mixing and $B(K_L\to\pi^0\nu\bar{\nu})$, and try to search for mixing of the fourth generation in the hierarchical mixing scheme of the Wolfenstein parametrization. Using the results for the mixing of the fourth generation, we discuss predictions of the $D^0-\bar{D^0}$ mixing ($\Delta m_D$) and the branching ratio of directly CP-violating decay process $K_L\to\pi^0\nu\bar{\nu}$, and the effects on the CP asymmetry in neutral B meson decays and the unitarity triangle.Comment: 29 pages written in LaTex. 6 figures(drawn on LaTeX). Revised from "$K^+\to\pi^+\nu\bar{\nu}$ in the four-generation model" of the same Authors(TOKUSHIMA 99-1, January 1999). A minor chang

CP violation effect in long-baseline neutrino oscillation in the four-neutrino model

We investigate CP-violation effect in the long-baseline neutrino oscillation in the four-neutrino model with mass scheme of the two nearly degenerate pairs separated with the order of 1 eV, by using the data from the solar neutrino deficit, the atmospheric neutrino anomaly and the LSND experiments along with the other accelerator and reactor experiments. By use of the most general parametrization of the mixing matrix with six angles and six phases, we show that the genuine CP-violation effect could attain as large as 0.3 for $\Delta P(\nu_\mu\to\nu_\tau) \equiv P(\nu_\mu\to\nu_\tau) - P(\bar{\nu_\mu}\to\bar{\nu_\tau})$ and that the matter effect is negligibly small such as at most 0.01 for $\Delta P(\nu_\mu\to\nu_\tau)$ for $\Delta m^2 = (1-5)\times 10^{-3} {\rm eV}^2$, which is the mass-squared difference relevant to the long-baseline oscillation.Comment: 21 pages in LaTeX, 9 ps figures. Some changes in the Introduction and Reference

New Physics in CP Asymmetries and Rare B Decays

We review and update the effects of physics beyond the standard model on CP asymmetries in B decays. These asymmetries can be significantly altered if there are important new-physics contributions to \bqbqbar mixing. This same new physics will therefore also contribute to rare, flavor-changing B decays. Through a study of such decays, we show that it is possible to partially distinguish the different models of new physics.Comment: 42 pages, plain TeX (macros included), 1 figure (included). A few sentences added, references updated. Present manuscript is now identical to the version accepted for publication in Phys. Rev.

Structural investigation of mechanically activated ZnO powder

Commercially available ZnO powder was mechanically activated in a planetary ball mill. In order to investigate the specific surface area, pore volume and microstructure of non-activated and mechanically activated ZnO powders the authors performed N-2 physisorption, SEM and TEM. Crystallite size and lattice microstrain were analyzed by X-ray diffraction method. XRD patterns indicate that peak intensities are getting lower and expend with activation time. The reduction in crystallite size and increasing of lattice microstrain with prolonged milling time were determined applying the Rietveld's method. The difference between non-activated and the activated powder has been also observed by X-ray photoelectron spectroscopy (XPS). XPS is used for investigating the chemical bonding of ZnO powder by analyzing the energy of photoelectrons. The lattice vibration spectra were obtained using Raman spectroscopy. In Raman spectra some changes along with atypical resonant scattering were noticed, which were caused by mechanical activation

The analysis of 2-amino-2-thiazoline-4-carboxylic acid in the plasma of smokers and non-smokers

ATCA (2-amino-2-thiazoline-4-carboxylic acid) is a promising marker to assess cyanide exposure because of several advantages of ATCA analysis over direct determination of cyanide and alternative cyanide biomarkers (i.e. stability in biological matrices, consistent recovery, and relatively small endogenous concentrations). Concentrations of ATCA in the plasma of smoking and non-smoking human volunteers were analyzed using gas-chromatography mass-spectrometry to establish the feasibility of using ATCA as a marker for cyanide exposure. The levels of ATCA in plasma of smoking volunteers, 17.2 ng/ml, were found to be significantly (p < 0.001) higher than that of non-smoking volunteers, 11.8 ng/ml. Comparison of ATCA concentrations of smokers relative to non-smokers in both urine and plasma yielded relatively similar results. The concentration ratio of ATCA for smokers versus non-smokers in plasma and urine was compared to similar literature studies of cyanide and thiocyanate, and correlations are discussed. This study supports previous evidence that ATCA can be used to determine past cyanide exposure and indicates that further studies should be pursued to validate the use of ATCA as a marker of cyanide exposure

The Top Quark Decay Vertex in Standard Model Extensions

New physics interactions can affect the strength and structure of the $tbW$ vertex. We investigate the magnitudes and phases of "anomalous" contributions to this vertex in a two-Higgs doublet and the minimal supersymmetric extension of the standard model, and in a top-color assisted technicolor (TC2) model. While the magnitudes of the anomalous couplings remain below 1 percent in the first two models, TC2 interactions can reduce the left-chiral coupling $f_L$ by several percent.Comment: Latex, 27 pages, 14 figure

Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study

<p>Abstract</p> <p>Background</p> <p>Macrocytosis occurs in chronic hemodialysis (CHD) patients; however, its significance is unknown. The purpose of this study was to establish the prevalence and distribution of macrocytosis, to identify its clinical associations and to determine if macrocytosis is associated with mortality in stable, chronic hemodialysis patients.</p> <p>Methods</p> <p>We conducted a single-centre prospective cohort study of 150 stable, adult CHD patients followed for nine months. Macrocytosis was defined as a mean corpuscular volume (MCV) > 97 fl. We analyzed MCV as a continuous variable, in tertiles and using a cutoff point of 102 fl.</p> <p>Results</p> <p>The mean MCV was 99.1 ± 6.4 fl, (range 66-120 fl). MCV was normally distributed. 92 (61%) of patients had an MCV > 97 fl and 45 (30%) > 102 fl. Patients were not B12 or folate deficient in those with available data and three patients with an MCV > 102 fl had hypothyroidism. In a logistic regression analysis, an MCV > 102 fl was associated with a higher Charlson-Age Comorbidity Index (CACI) and higher ratios of darbepoetin alfa to hemoglobin (Hb), [(weekly darbepoetin alfa dose in micrograms per kg body weight / Hb in g/L)*1000]. There were 23 deaths at nine months in this study. Unadjusted MCV > 102 fl was associated with mortality (HR 3.24, 95% CI 1.42-7.39, P = 0.005). Adjusting for the CACI, an MCV > 102 fl was still associated with mortality (HR 2.47, 95% CI 1.07-5.71, P = 0.035).</p> <p>Conclusions</p> <p>Macrocytosis may be associated with mortality in stable, chronic hemodialysis patients. Future studies will need to be conducted to confirm this finding.</p

Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

<p>Abstract</p> <p>Background</p> <p>Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule.</p> <p>Methods</p> <p>Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m²/day) intravenously for 12 to 14 days.</p> <p>Results</p> <p>We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF.</p> <p>Conclusions</p> <p>Intravenous rh-HGF at a dose of 0.6 mg/m²was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.</p

Ankyrin is the major oxidised protein in erythrocyte membranes from end-stage renal disease patients on chronic haemodialysis and oxidation is decreased by dialysis and vitamin C supplementation

Chronically haemodialysed end-stage renal disease patients are at high risk of morbidity arising from complications of dialysis, the underlying pathology that has led to renal disease and the complex pathology of chronic kidney disease. Anaemia is commonplace and its origins are multifactorial, involving reduced renal erythropoietin production, accumulation of uremic toxins and an increase in erythrocyte fragility. Oxidative damage is a common risk factor in renal disease and its co-morbidities and is known to cause erythrocyte fragility. Therefore, we have investigated the hypothesis that specific erythrocyte membrane proteins are more oxidised in end-stage renal disease patients and that vitamin C supplementation can ameliorate membrane protein oxidation. Eleven patients and 15 control subjects were recruited to the study. Patients were supplemented with 2 × 500 mg vitamin C per day for 4 weeks. Erythrocyte membrane proteins were prepared pre- and post-vitamin C supplementation for determination of protein oxidation. Total protein carbonyls were reduced by vitamin C supplementation but not by dialysis when investigated by enzyme linked immunosorbent assay. Using a western blot to detect oxidised proteins, one protein band, later identified as containing ankyrin, was found to be oxidised in patients but not controls and was reduced significantly by 60% in all patients after dialysis and by 20% after vitamin C treatment pre-dialysis. Ankyrin oxidation analysis may be useful in a stratified medicines approach as a possible marker to identify requirements for intervention in dialysis patients

Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease:A Case-Control Study

Inflammation induced by infectious and noninfectious triggers in the kidney may lead to end stage renal disease (ESRD). Toll-like receptor 9 (TLR-9) a receptor for CpG DNA is involved in activation of immune cells in renal disease and may contribute to chronic inflammatory disease progression through an interleukin-6 (IL-6) dependent pathway. Previous studies indicate that -1237T/C confers regulatory effects on TLR-9 transcription. To date the effect of TLR-9 polymorphisms on ESRD remains unknown. We performed a case-control study and genotyped 630 ESRD patients and 415 controls for -1237T/C, -1486T/C and 1635G/A by real-time PCR assays and assessed plasma concentration of IL-6 by ELISA. Haplotype association analysis was performed using the Haploview package. A luciferase reporter assay and real-time PCR were used to test the function of the -1237T/C promoter polymorphism. A significant association between -1237T/C in TLR-9 and ESRD was identified. The TCA, TTA and CCA haplotype of TLR-9 were associated with ESRD. ESRD patients carrying -1237TC had a higher mean plasma IL-6 level when compared with -1237TT. The TLR-9 transcriptional activity of the variant -1237CC allele is higher than the -1237TT allele. The results indicate that in a Han Chinese population the presence of the C allele of -1237T/C in the TLR-9 gene increases susceptibility towards development of ESRD. In vitro studies demonstrate that -1237T/C may be involved in the development of ESRD through transcriptional modulation of TLR-9